$MIRA News

MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study

MIRA Pharma Reports 21-Day Preclinical Proof-Of-Concept Study Showing That Once-Daily Oral MIRA-55 Significantly Reduced Mechanical And Thermal Pain Hypersensitivity; Results Back MIRA-55's Progress Toward IND Filing

MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review

Maxim Group Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $3.5

MIRA Pharmaceuticals Submits Phase 2a Ketamir‑2 Protocol For CIPN To IRB, Incorporating FDA Feedback And Targeting Q1 2027 Site Initiation

Why Is MIRA Pharmaceuticals Stock Gaining Tuesday?

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

MIRA Pharma Announces Results Preclinical Studies Evaluating Optimized Oral Formulations Of MIRA-55, Oral Drug Candidate Being Developed As Non-Opioid Therapy For Chronic Inflammatory Pain

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

MIRA Pharmaceuticals Reports Data From Its SKNY-1 Oral Formulation To Treat Obesity, Addiction-Related Disorders

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

MIRA Pharmaceuticals Announces New Preclinical Data On Mira-55 Cannabinoid Analog In Development For Chronic Inflammatory Pain Showing Favorable Anxiety-Reducing Effect While Delivering Pain Relief

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

MIRA Pharmaceuticals Files Phase 2a Clinical Study Protocol To FDA For Ketamir-2 Oral NMDA Receptor Modulator

Mira Pharmaceuticals Appoints Andriy Mushak As Fractional CFO Following Departure Of CFO Alan Weichselbaum, Effective June 6, 2026

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

MIRA Pharma Executes Amended And Restated Exclusive License Agreement With MIRALOGX, Securing Worldwide Exclusive Rights To MIRA-55 And SKNY-1